|
Facebook
Twitter
Linkedin
|
 |
 |
 |
 |
Healthcare Company News 
Imaging Diagnostic Systems, Inc. Imaging Diagnostic Systems Continues to Expand Its International Marketing Efforts
Imaging Diagnostic Systems, Inc. Imaging Diagnostic Systems Continues to Expand Its International Marketing Efforts
Imaging Diagnostic Systems Continues to Expand Its International Marketing Efforts
Friday, 20 March 2009 01:55 | 
| Company News - Imaging Diagnostic Systems, Inc. |
IDSI Appoints New Distributor for Australia, New Zealand and China Experienced in Launching Innovative Medical Technologies
Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast cancer imaging systems, announced that Jainsons Pty Ltd Company has been appointed as the new distributor for its CT Laser Mammography system for Australia, New Zealand and China.
Dr. Mukesh Jain, Chairman of Jainsons Pty Ltd, commented, “This is a very innovative and exciting technological breakthrough for breast cancer detection. This can revolutionize the breast cancer industry and has great potential in the Asian market. I believe that with time, this technology will be an alternative method to mammography.”
Jainsons Pty Ltd is a medical equipment distribution company with over 15 years experience in launching new technologies to the medical markets with a focus in laser medical technologies. The company has offices in Australia, India and the Philippines and agents throughout Asia.
Breast cancer is the most commonly diagnosed cancer in Australian women, with 1 in 11 who will develop breast cancer before the age of 75. In New Zealand, 1 in 9 women are diagnosed with breast cancer.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a patented new breast imaging system that utilizes continuous wave laser technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification. For more information, visit corporate website: www.imds.com.
Source: Imaging Diagnostic Systems, Inc.
Dr. Mukesh Jain, Chairman of Jainsons Pty Ltd, commented, “This is a very innovative and exciting technological breakthrough for breast cancer detection. This can revolutionize the breast cancer industry and has great potential in the Asian market. I believe that with time, this technology will be an alternative method to mammography.”
Jainsons Pty Ltd is a medical equipment distribution company with over 15 years experience in launching new technologies to the medical markets with a focus in laser medical technologies. The company has offices in Australia, India and the Philippines and agents throughout Asia.
Breast cancer is the most commonly diagnosed cancer in Australian women, with 1 in 11 who will develop breast cancer before the age of 75. In New Zealand, 1 in 9 women are diagnosed with breast cancer.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a patented new breast imaging system that utilizes continuous wave laser technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification. For more information, visit corporate website: www.imds.com.
Source: Imaging Diagnostic Systems, Inc.
